Firm halting sales of dietary supplement Anatabloc

by Michael Felberbaum

The dietary supplement maker at the center of a federal trial of former Virginia Gov. Bob McDonnell and his wife says it's halting sales of its product called Anatabloc.

Rock Creek Pharmaceuticals Inc. said Monday it is voluntarily stopping sales while it sorts out issues with the Food and Drug Administration.

Last year, the federal agency sent a warning letter to the company known as Star Scientific saying that its products contain a new dietary ingredient that requires approval before it can be marketed.

The agency also said the company's website had improperly promoted Anatabloc as a drug by suggesting it can be used to treat various diseases.

The McDonnells are charged with accepting gifts and loans from Star Scientific's former CEO in exchange for promoting his products.

Related Stories

FDA warns of steroids in vitamin B supplement

date Jul 27, 2013

(AP)—The Food and Drug Administration is warning consumers to avoid a vitamin B dietary supplement from Healthy Life Chemistry by Purity First because it contains two potentially dangerous anabolic steroids.

Orbactiv approved for drug-resistant skin infections

date Aug 07, 2014

(HealthDay)—The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.

Virginia tobacco maker seeks new FDA designation

date Jan 04, 2011

(AP) -- Tobacco maker Star Scientific Inc. says it has developed a moist smokeless tobacco with lower levels of cancer-causing chemicals than any other tobacco product now on the market.

US watchdog warns on fitness stimulant

date Apr 27, 2012

The US Food and Drug Administration on Friday questioned the safety of DMAA, a stimulant used in dietary supplements, alleging that marketers were illegally selling the chemical.

Recommended for you

Questions over value of new antibiotics to tackle resistance

date 17 hours ago

In the first installment of a new series, Peter Doshi, Assistant Professor at the University of Maryland School of Pharmacy and Associate Editor at The BMJ, asks why authorities are approving drugs with little evidence they d ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.